Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity. (16th March 2022)

• Record Type: Journal Article
• Authors: Zeng, Wanying; Zhang, Qing; Zhu, Yangmin; Ou, Ruiming; Peng, Liang; Wang, Baolei; Shen, Huijuan; Liu, Zhi; Lu, Lisheng; Zhang, Pumin; Liu, Shuang
• Is Part Of: Cancer investigation. Volume 40:Number 3(2022)
• Page Start: 282
• Page End: 292
• Publication Date: 2022-03-16
• Subjects: CAR-T cells -- B-cell malignant tumors -- CD19 -- CD22; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2021.2005798
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Despite high remission rates following chimeric antigen receptor T cell (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL), relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may improve the CAR-T effect. The in vitro and in vivo leukemia model was established, and the anti-tumor effects of BiCAR-T, CD19 CAR-T, CD22 CAR-T, and LoopCAR6 cells were observed. We found that the BiCAR-T cells showed significant cytotoxicity in vitro and in vivo . The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce the risk of antigen loss.